Zai Lab (ZLAB) Stock: Buy, Sell, or Hold?
ZLAB - Zai Lab Limited American Depositary Shares
$25.50
-0.84 (-3.19%)
âŧ
5d:
+0.87%
30d:
+0.79%
90d:
+33.37%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When ZLAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ZLAB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ZLAB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ZLAB is currently trading at $25.50, which is considered slightly high relative to its 30-day fair value range of $24.91 to $26.43.
Technical Outlook: Technically, ZLAB is in a strong uptrend. The price is currently testing key support at $24.81. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $33.14 (+30.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZLAB is in a strong uptrend. The price is currently testing key support at $24.81. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $33.14 (+30.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$24.91 -
$26.43
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.6%
All Signals
- NEUTRAL: Mixed technical signals (41/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 30.0% below Wall St target ($33.14)
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$24.91 -
$26.43
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$24.81
Resistance Level
$27.14
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.08
Wall Street Target
$33.14
(+30.0%)
Revenue Growth (YoY)
-3.3%
Profit Margin
-41.9%
Share & Embed Analysis
Last updated: October 02, 2026 7:03 AM ET
Data refreshes hourly during market hours. Next update: 8:03 AM
Data refreshes hourly during market hours. Next update: 8:03 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZLAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Rafael Amado
SELL
2739 shares
2026-04-06
Yajing Chen
SELL
853 shares
2026-04-06
Ying Du
SELL
2653 shares
2026-04-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$92 | 59 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 73 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 44 HOLD |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 62 BUY |
